No Data
No Data
CVRx to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call on July 29th, 2024
MINNEAPOLIS, July 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim, an innovative
CVRx, Inc.'s (NASDAQ:CVRX) Market Cap Dropped US$70m Last Week; Individual Investors Who Hold 44% Were Hit as Were Institutions
Key Insights Significant control over CVRx by private equity firms implies that the general public has more power to influence management and governance-related decisions 53% of the business is
Strength Seen in CVRx (CVRX): Can Its 19.0% Jump Turn Into More Strength?
CVRx Is Maintained at Buy by Lake Street
CVRx Is Maintained at Buy by Lake
CVRx Price Target Cut to $12.00/Share From $18.00 by Lake Street
CVRx Price Target Cut to $12.00/Share From $18.00 by Lake
Lake Street Maintains Buy on CVRx, Lowers Price Target to $12
Lake Street analyst Frank Takkinen maintains CVRx (NASDAQ:CVRX) with a Buy and lowers the price target from $18 to $12.
No Data